
Access to medicines: Will history repeat itself?
Rebutting pharma’s rejection of a global COVID-19 IP waiver By Felipe Carvalho, Yuanqiong Hu, Leena Menghaney In response to the COVID-19 “TRIPS waiver” proposal submitted by South Africa and India for a temporary waiver from certain pharmaceutical












